We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -0.12% | 32.77 | 32.74 | 33.00 | 33.03 | 32.73 | 33.00 | 1,281,689 | 21:15:00 |
From May 2019 to May 2024
By Michael Dabaie
AC Immune SA said a Phase 2 trial of semorinemab didn't meet the co-primary efficacy endpoint or two secondary endpoints for early Alzheimer's disease.
Swiss-based clinical-stage biopharmaceutical company AC Immune said its partner, Roche Group's Genentech, informed the company of the top-line results of the trial, which showed semorinemab didn't meet its co-primary goal of reducing the decline on Clinical Dementia Rating-Sum of Boxes compared to a placebo.
The secondary endpoints of Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative Study Group -- Activities of Daily Living Inventory also weren't met, AC Immune said.
The company said additional data analyses are ongoing and Genentech plans to present the results from the trial at an upcoming medical congress. The second Phase 2 study of semorinemab in patients with moderate Alzheimer's disease remains ongoing, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 23, 2020 07:44 ET (11:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
